UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Phase II Trial of Methotrexate in Myasthenia Gravis (MG Study)
  • Purpose: to find out if methotrexate is an effective therapy for MG and if it will allow patients with MG to use less prednisone.
  • Eligibility: patients ages 15 and older with MG who are on a stable dose of Prednisone 10 mg per day or greater.
  • Duration and Involvement: patients will take study medication (methotrexate 20 mg vs. placebo) by mouth once weekly and return to clinic once per month for approximately 14 months.
Start Date
August 31, 2012
End Date
February 28, 2013
Gender Preference
Age Group
15 - 99 years
Principal Investigator
Andrea Swenson, MD
Contact Info

Jeri Sieren, RN at 319-356-8744

Methotrexate ; Neurology ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.